KR20060084083A - Method for Purifying Painol Intradermal - Google Patents
Method for Purifying Painol Intradermal Download PDFInfo
- Publication number
- KR20060084083A KR20060084083A KR1020050004083A KR20050004083A KR20060084083A KR 20060084083 A KR20060084083 A KR 20060084083A KR 1020050004083 A KR1020050004083 A KR 1020050004083A KR 20050004083 A KR20050004083 A KR 20050004083A KR 20060084083 A KR20060084083 A KR 20060084083A
- Authority
- KR
- South Korea
- Prior art keywords
- paeonol
- content
- extract
- purifying
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 claims abstract description 136
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 claims abstract description 68
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 claims abstract description 68
- 238000010438 heat treatment Methods 0.000 claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 14
- 230000002708 enhancing effect Effects 0.000 claims abstract description 8
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 229920005654 Sephadex Polymers 0.000 claims description 4
- 239000012507 Sephadex™ Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 238000005192 partition Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 abstract description 11
- 230000001965 increasing effect Effects 0.000 abstract description 11
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 6
- 230000001093 anti-cancer Effects 0.000 abstract description 5
- -1 antioxidant Chemical class 0.000 abstract description 5
- 239000003963 antioxidant agent Substances 0.000 abstract description 5
- 206010039897 Sedation Diseases 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000036280 sedation Effects 0.000 abstract description 4
- 230000003511 endothelial effect Effects 0.000 abstract description 2
- 238000002481 ethanol extraction Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 22
- 239000000469 ethanolic extract Substances 0.000 description 13
- 230000008859 change Effects 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000004821 distillation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 240000005001 Paeonia suffruticosa Species 0.000 description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000004322 Canarium indicum Nutrition 0.000 description 1
- 240000005209 Canarium indicum Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 244000130503 Saccharum sinense Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- RQBBFKINEJYDOB-UHFFFAOYSA-N acetic acid;acetonitrile Chemical compound CC#N.CC(O)=O RQBBFKINEJYDOB-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008820 moutan cortex Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/825—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 목단피내에서 파에오놀의 함량을 증강시키는 방법 및 상기 방법에 의하여 함량이 증강된 파에오놀을 정제하는 방법에 관한 것으로, The present invention relates to a method for enhancing the content of paeonol in the neck skin and to a method for purifying paeonol content enhanced by the above method,
목단피를 가열처리하여 목단피내 파에오놀의 함량을 증강시키는 방법, 이와같이 하여 얻어진 파에오놀의 함량이 증강된 목단피에 에탄올 추출, 용해도차 및 각종 크로마토그라피를 이용하여 파에오놀을 정제하는 방법이 제공된다. There is provided a method for enhancing the content of paeonol in the endothelial skin by heating the neck skin, and a method for purifying paonol by using ethanol extraction, solubility difference and various chromatography in the neck skin with the content of paeonol obtained in this way.
본 발명에 의하면, 항산화, 항염증, 항암, 진정작용, 동맥경화 저해등 활성화합물인 파에오놀 함량을 증강시켜 추출해낼 수 있다.According to the present invention, it is possible to extract by increasing the content of paeonol active compounds such as antioxidant, anti-inflammatory, anti-cancer, sedation, inhibiting atherosclerosis.
목단피, 가열, 파에오놀, 함량, 추출, 정제Bark Peel, Heating, Paeonol, Content, Extract, Purification
Description
도 1은 본 발명의 일 실시예로서 목단피내 활성 화합물로서 파에오놀의 함량을 증강시킨 다음 그 추출물로부터 파에오놀을 추출하는 방법을 도시한 흐름도이며, 1 is a flow chart illustrating a method of extracting paeonol from the extract after enhancing the content of paeonol as an active compound in the dermis as an embodiment of the present invention,
도 2는 본 발명의 가열처리전후 목단피내 파에오놀의 함량변화를 측정한 HPLC 크로마토그램이며,Figure 2 is an HPLC chromatogram measuring the change in the content of paeool in the neck skin before and after heat treatment of the present invention,
도 3은 본 발명의 일실시예에 의해 정제된 파에오놀의 수소 핵자기 공명 스펙트럼이며, 3 is a hydrogen nuclear magnetic resonance spectrum of paeonol purified according to an embodiment of the present invention,
도 4는 본 발명의 일실시예에 의해 정제된 파에오놀의 탄소 핵자기 공명 스펙트럼이며, 4 is a carbon nuclear magnetic resonance spectrum of paeonol purified according to an embodiment of the present invention,
도 5는 본 발명의 가열처리시 온도별 파에오놀 함량변화를 측정하여 도시한 그래프이며, 그리고 5 is a graph showing the measurement of the change in paeonol content for each temperature during the heat treatment of the present invention, and
도 6은 본 발명의 가열처리후 목단피의 에탄올 추출물에 대한 DPPG 라디칼 소거능을 나타낸 항산화 활성비교 그래프이다. 6 is an antioxidant activity comparison graph showing the DPPG radical scavenging ability of the ethanol extract of the bark skin after heat treatment of the present invention.
본 발명은 목단피내에서 파에오놀의 함량을 증강시키는 방법 및 상기 방법에 의하여 함량이 증강된 파에오놀을 정제하는 방법에 관한 것으로, 보다 상세하게는 가열처리한 목단피 추출물로부터 항산화, 항염증, 항암, 진정작용, 동맥경화 저해 등의 활성화합물인 파에오놀의 함량을 증강시키고, 상기 추출물로부터 활성화합물인 파에오놀을 효과적으로 추출하는 방법에 관한 것이다.The present invention relates to a method of enhancing the content of paeonol in the neck skin and to a method of purifying paeonol content enhanced by the above method, more specifically, antioxidant, anti-inflammatory, anti-cancer, The present invention relates to a method for enhancing the content of paeonol, an active compound such as sedation and inhibiting atherosclerosis, and effectively extracting paonol, an active compound, from the extract.
일반적으로, 목단피(Moutan Cortex)는 갈잎떨기나무에 속하는 모란(Paeonia moutan Sims., Paeonia suffruticosa Andrews)의 뿌리껍질로 관상 - 반관상을 이루고, 외면은 암갈색 - 자갈색을 나타내고 가로로 길며, 작은 원형인 측근의 자국과 세로주름이 있고, 내면은 엷은 회갈색을 나타낸다고 알려져 있다. 이러한, 목단피에 함유된 것으로 알려진 파에오놀(paeonol)은 문헌에 보고된 바에 의하면 항산화, 항염증, 항암, 진정작용, 동맥경화 저해 등의 다양한 생리활성을 나타내는 것으로 알려져 있다. Generally, mokdanpi (Moutan Cortex) is galip bush coronary into root bark of peony (Paeonia moutan Sims, Paeonia suffruticosa Andrews .) Belongs to the tree - form the half-tubular outer surface is dark brown - represents a purplish brown long horizontally, a small circle It is known to have side marks and vertical wrinkles, and its inner surface has a light grayish brown color. Paeonol, which is known to be contained in the bark skin, is reported in the literature to exhibit various physiological activities such as antioxidant, anti-inflammatory, anticancer, sedative, and atherosclerosis inhibition.
이같은 파에오놀의 화학식은 다음과 같다. The chemical formula of such paeonol is as follows.
문헌에 보고된 바에 의하면, 파에오놀의 항산화 작용에 관한 문헌으로는 Tang, Jingrong; Shi, Lin; Li, Shengting.에 의한 “파에오놀이 정상 및 칼슘파라독스 배양된 신생 쥐 심근세포내 지질 퍼옥시다제에 미치는 영향” Zhongcaoyao (1990), 21(12), 547-549” 및 Tang, J; Shi, L;에 의한 “칼슘 파라독스도중 배양된 신생 쥐 심장 세포에 대한 파에오놀의 보호 효과”. Zhongguo zhong yao za zhi (1991), 16(9), 557-569등이 있으며, 항염증 작용에 관한 문헌으로는 Chou, Tz-Chong.에 의한 “가라기난-유발시킨 열 과민증내 파에오놀의 항염증 및 진통효과.” British Journal of Pharmacology (2003), 139(6), 1146-1152 및 Wu, Guanzhong; Hang, Bingqian; Hang, Jingxia; Ling, Gengxin.에 의한 “파에오놀의 항염증 효과 및 그 메카니즘.” Zhongguo Yaoke Daxue Xuebao (1989), 20(3), 147-150등이 있으며, 항암작용에 관한 문헌으로는 Sun, Guoping; Shen, Yuxian; Zhang, Lingling; Zhou, Aiwu; Wei, Wei; Xu, Shuyun. “HepA 종양 쥐내 파에오놀의 면역조절 및 항종양 활성에 대한 연구.” Zhongguo Yaolixue Tongbao (2003), 19(2), 160-162등이 있으며, 진정작용에 관한 문헌으로는 김승훈, 김성애, 박미경, 김성형, 박영두, 나호정, 김형민, 신민규, 안규석에 의한 “파에오놀은 히스타민 및 TNF-α를 조절함으로써 아낙필락시성(anaphylactic) 작용을 억제한다.” International immunopharmacology (2004), 4(2), 279-287 및 Wu, Guanzhong; Hang, Bingqian; Hang, Jingxia; Lin, Gengxin.에 의한 “파에오놀의 항과민성 효과.” Zhongguo Yaoke Daxue Xuebao (1990), 21(2), 103-106등이 있으며, 동맥경화 저해에 관한 문헌으로는 Dai, Min; Zhi, Xiaomei; Peng, Daiyin; Liu, Qungyun. “메추라기내 실험적인 동맥경화증에 대한 파에오놀의 억제 효과.” Zhongguo Zhongyao Zazhi (1999), 24(8), 488-490), 등을 들 수 있다. As reported in the literature, literature on the antioxidant activity of paeonol includes Tang, Jingrong; Shi, Lin; Li, Shengting. “Effects of Paeool on Lipid Peroxidase in Normal and Calcium Paradox Cultured Neonatal Myocardial Cells” Zhongcaoyao (1990), 21 (12), 547-549 ”and Tang, J; "Protective Effect of Paeonol on New Rat Cardiac Cells Cultured During Calcium Paradox" by Shi, L ;. Zhongguo zhong yao za zhi (1991), 16 (9), 557-569, and the literature on anti-inflammatory action is described by Chou, Tz-Chong. Inflammatory and analgesic effects. ”British Journal of Pharmacology (2003), 139 (6), 1146-1152 and Wu, Guanzhong; Hang, Bingqian; Hang, Jingxia; Ling, Gengxin. “Anti-inflammatory Effects of Paeonol and Its Mechanisms.” Zhongguo Yaoke Daxue Xuebao (1989), 20 (3), 147-150, et al., Sun, Guoping; Shen, Yuxian; Zhang, Lingling; Zhou, Aiwu; Wei, Wei; Xu, Shuyun. “Study on the immunomodulation and antitumor activity of paeonol in HepA tumor rats.” Zhongguo Yaolixue Tongbao (2003), 19 (2), 160-162, etc. The literature on sedation is Kim Seung-hoon, Kim Sung-ae, Park Mi-kyung, By Kim, Sung-Hyung, Young-Doo Park, Ho-Jung Na, Hyung-Min Kim, Min-Kyu Shin, and Kyu-Seok Ahn, “Paeonol inhibits anaphylactic action by regulating histamine and TNF-α.” International immunopharmacology (2004), 4 (2), 279-287 and Wu, Guanzhong; Hang, Bingqian; Hang, Jingxia; Lin, Gengxin. “Anti-sensitizing effect of paeolol.” Zhongguo Yaoke Daxue Xuebao (1990), 21 (2), 103-106, et al., Dai, Min; Zhi, Xiaomei; Peng, Daiyin; Liu, Qungyun. "The inhibitory effect of paeonol on experimental atherosclerosis in quails." Zhongguo Zhongyao Zazhi (1999), 24 (8), 488-490).
한편, 목단피내 파에오놀과 관련한 종래 기술로는 중국 특허공개 제1331968(20020123)호와 1142338(19970212)호가 있으나, 상기 특허들은 각각 파에오놀이 함유된 치약 제조, 및 파에오놀이 함유된 심장병 예방용 건강담배의 제조방법에 불과한 것이다. 국내외를 막론하고 목단피중 파에오놀 함량을 증가시키는 기술 및 이같이 함량이 증강된 파에오놀을 추출해내는 방법은 찾아볼 수 없었다. Meanwhile, prior arts related to intradermal paeolol have been disclosed in Chinese Patent Publication Nos. 1331968 (20020123) and 1142338 (19970212), but the patents are for the manufacture of toothpaste containing paeonole and for preventing heart disease containing paeonole, respectively. It is just a method of manufacturing health tobacco. No technique has been found to increase the content of paeonol in the skin of both neck and neck, and to extract paeonol with such enhanced content.
이에 본 발명의 목적은 목단피내 활성화합물인 파에오놀의 함량을 증가시키는 방법을 제공하려는 것이다. Accordingly, an object of the present invention is to provide a method for increasing the content of paeonol, the active compound in the bark skin.
본 발명의 다른 목적은 파에오놀 함량이 증가시키도록 처리한 목단피로부터 파에오놀을 정제하는 방법을 제공하려는 것이다. Another object of the present invention is to provide a method for purifying paeonol from bark skins treated to increase the paeonol content.
본 발명의 일견지에 의하면, According to one aspect of the invention,
목단피를 50-210℃에서 5-60분간 가열처리하는 것을 특징으로 하는 목단피내 파에오놀의 함량을 증강시키는 방법이 제공된다. Provided is a method for enhancing the content of paeonol in the endothelial skin, wherein the neck skin is heated at 50-210 ° C. for 5-60 minutes.
본 발명의 제2견지에 의하면, According to the second aspect of the present invention,
제1견지의 방법에 의해 파에오놀의 함량이 증강된 목단피를 에탄올로 추출하여 추출물을 얻는 단계; Extracting the bark skin with increased content of paeolol by ethanol according to the first method;
상기 추출물을 물에 분산시켜 디클로로메탄, 클로로포름, 에틸아세테이트, 에테르 및 에탄올로 이루어진 그룹으로부터 선택된 1종의 용매로 1회 내지 5회 분배 추출한 뒤 농축하여 유기용매 가용성 분획을 얻는 단계; 및 Dispersing the extract in water to extract one to five portions of a solvent selected from the group consisting of dichloromethane, chloroform, ethyl acetate, ether and ethanol, and then concentrating to obtain an organic solvent soluble fraction; And
상기 유기용매 가용성 분획을 메탄올, 헥산, 아세트산, 에틸아세테이트, 개미산, 클로로포름, 벤젠 및 이들로부터 선택된 2종이상을 혼합한 용매로 이루어진 그룹으로부터 선택된 용매를 이용하여 실리카젤, 역상 실리카젤, 고속액체 및 세파덱스(Sephadex)로 이루어진 그룹으로부터 선택된 담체를 이용한 크로마토그라피를 사용하여 파에오놀을 정제하는 단계;를 포함하여 이루어지는 목단피내 파에오놀의 정제방법이 제공된다. Silica gel, reverse phase silica gel, fast liquid, and the organic solvent soluble fraction using a solvent selected from the group consisting of methanol, hexane, acetic acid, ethyl acetate, formic acid, chloroform, benzene and a solvent mixed with two or more selected from them. Purifying paeonol using a chromatography selected from the group consisting of Sephadex (Sephadex) using paeolol; there is provided a method for purifying intradermal paeool.
이하, 본 발명에 대하여 첨부된 도 1을 참조하여 상세하게 설명한다. Hereinafter, with reference to the accompanying Figure 1 with respect to the present invention will be described in detail.
목단피내 활성 화합물인 파에오놀은 목단피를 가열처리함으로서 그 함량을 극대화하게 된다. 그 가열온도는 50~210℃에서 5~60분간, 바람직하게는 140~200℃에서 20~60분간, 가장 바람직하게는 180~200℃에서 20~60분간 가열처리하는 것 이 좋다. 상기 범위를 벗어나면 파에오놀의 함량을 의도하는 만큼 충분히 증강시킬 수 없으므로 바람직하지 않다. Paeonol, the active compound in bark dermis, maximizes its content by heating the bark. The heating temperature is 5 to 60 minutes at 50 to 210 ° C, preferably 20 to 60 minutes at 140 to 200 ° C, and most preferably 20 to 60 minutes at 180 to 200 ° C. Outside the above range, it is not preferable because the content of paeonol cannot be sufficiently enhanced as intended.
이때 가열을 위한 기계로는 자체 제작한 전기볶음 기계뿐 아니라 가열기, 가압기등 목단피를 적절하게 가열할 수 있는 기계라면 어떤 종류든지 사용가능하다. In this case, any kind of machine for heating can be used as long as the machine can properly heat the wood skin such as a heater, a pressurizer, as well as a self-cooking machine.
이와같이 파에오놀 함량을 증가시킨 목단피를 에탄올로 추출하여 에탄올 추출물을 얻는다. 에탄올 농도로는 50~100%, 바람직하게는 80~95%, 가장 바람직하게는 95%인 것을 사용하는 것이 좋으며, 얻어진 추출물을 증류, 감압증류, 스프레이 드라이등 공지된 방법을 사용하여 건조시키는 것이 보다 바람직하다. Thus, ethanol extract is obtained by extracting the bark skin with increased paeonol content with ethanol. As the ethanol concentration, it is preferable to use 50 to 100%, preferably 80 to 95%, and most preferably 95%, and to dry the obtained extract by a known method such as distillation, distillation under reduced pressure, or spray drying. More preferred.
얻어진 추출물에 적정량, 바람직하게는 대략 3배량정도의 물을 가하여 분산시킨 다음, 디클로로메탄, 클로로포름, 에틸아세테이트, 에테르 및 에탄올로 이루어진 그룹으로부터 선택된 1종의 용매, 바람직하게는 에틸아세테이트나 클로로포름, 또는 디클로로메탄, 가장 바람직하게는 디클로로메탄을 분산시 사용한 물의 0.5~3배, 바람직하게는 물과 동량으로 사용하여 1~5회, 바람직하게는 2~3회, 가장바람직하게는 2회 분배추출한다. 이와같이 하여 얻어진 분배추출물은 농축시켜 유기용매 가용성 분획을 얻는다. The obtained extract is dispersed by adding an appropriate amount, preferably about 3 times, of water, and then one solvent selected from the group consisting of dichloromethane, chloroform, ethyl acetate, ether and ethanol, preferably ethyl acetate or chloroform, or Dichloromethane, most preferably dichloromethane, is 0.5 to 3 times the amount of water used for dispersing, preferably 1 to 5 times, preferably 2 to 3 times, and most preferably twice . The partition extract thus obtained is concentrated to obtain an organic solvent soluble fraction.
상기 유기용매 가용성 분획은 메탄올, 헥산, 아세트산, 에틸아세테이트, 개 미산, 클로로포름, 벤젠 및 이들로부터 선택된 2종이상을 혼합한 용매로 이루어진 그룹으로부터 선택된 용매를 이용하여 실리카젤, 역상 실리카젤, 고속액체 및 세파덱스(Sephadex)로 이루어진 그룹으로부터 선택된 담체, 바람직하게는 실리카젤을 이용한 컬럼크로마토그라피를 사용하여 분리하여 함량이 증강된 파에오놀 순수함유 분획을 얻게 된다. 실리카겔을 사용하는 경우 간단하고 경제적이며 분리능이 뛰어나 효울적이다. 한편, 상기 유기용매 가용성 분획은 분리하기에 앞서 증류, 감압증류, 또는 스프레이 드라이어등 공지된 방법을 사용하여 건조한 다음 농축시켜 사용하는 것이 보다 바람직하다. The organic solvent soluble fraction is a silica gel, reverse phase silica gel, high-speed liquid using a solvent selected from the group consisting of methanol, hexane, acetic acid, ethyl acetate, formic acid, chloroform, benzene and a solvent mixed with two or more selected from them. And Sepadex (Sephadex) is selected from the group consisting of a column chromatography using a carrier, preferably silica gel using a silica gel to obtain a pure content of paeonol content is enhanced. In case of using silica gel, it is simple and economical, and it is effective because of its excellent resolution. On the other hand, the organic solvent soluble fraction is more preferably used by drying and then concentrated using a known method such as distillation, distillation under reduced pressure, or a spray dryer prior to separation.
이와 같은 방법에 의하면, 목단피의 에탄올 추출물 1g당 파에오놀을 454.3±5.7mg 범위내까지 증강시켜 얻어낼 수 있는 것으로, 비단 목단피뿐 아니라 파에오놀을 함유하는 유사식물에 대하여도 상술한 공정들을 순차적으로 적용함으로써 동일 내지는 유사한 효과를 얻을 수 있다. According to this method, it is possible to obtain paeonol per 45 g of ethanol extract of the bark skin by increasing the range to 454.3 ± 5.7 mg, and the above-described steps are sequentially performed on not only silk bark but also similar plants containing paonol. The same or similar effects can be obtained by applying.
한편, 얻어진 파에오놀에 약학적, 향장품학적, 또는 식품학적 조성물로 허용되는 부형제, 담체, 희석제 등과 같은 상업적으로 이용가능한 성분들을 이용하여 공지의 방법에 따라 제제화할 수 있다.On the other hand, the obtained paeool may be formulated according to a known method using commercially available ingredients such as excipients, carriers, diluents and the like which are acceptable as pharmaceutical, cosmetic or food composition.
여기서 담체, 부형제 및 희석제로는 이에 한정하는 것은 아니나, 락토즈, 덱스트로즈, 슈크로즈, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산칼슘, 알지네이 트, 젤라틴, 규산칼슘, 미세결정성 셀룰로즈, 폴리비닐피롤리돈, 셀룰로즈, 폴리비닐피롤리돈, 셀룰로즈, 물, 설탕시럽, 메틸셀룰로즈, 메틸 하이드록시 벤조에이트, 프로필 하이드록시 벤조에이트, 활석, 스테아트산 마그네슘 및 미네랄 오일등을 들 수 있다. 그 사용가능한 함량은 이에 한정하는 것은 아니나, 100mg 내지 10g의 양으로 사용할 수 있다. Carriers, excipients and diluents include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, Polyvinylpyrrolidone, cellulose, polyvinylpyrrolidone, cellulose, water, sugar syrup, methylcellulose, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate and mineral oil . The usable content is not limited thereto, but may be used in an amount of 100 mg to 10 g.
또한, 상기 성분들 외에도 상업적으로 이용가능한 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.In addition to the above components, commercially available lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives and the like may further be included.
한편, 제제화의 일예로는, 활성 성분을 담체와 혼합 혹은 희석시킬 수 있으며, 또는 캡슐, 사셰, 종이 또는 다른 종류의 담체에 담을 수 있다. 이때, 담체는 희석제의 역할을 수행할 수 있도록 활성 성분을 위한 비히클, 부형제 또는 매질로 작용하는 고체, 반고체, 또는 액체 물질일 수 있다. 따라서, 결과적으로 얻어지는 제제는 정제, 환제, 분산제, 과립제, 엘릭서, 현탁제, 유화제, 용액, 시럽제, 에어로졸제, 연질 및 경질 젤라틴 캅셀제, 멸균 주사용액, 멸균 포장된 분말제 및 연고 등의 형태일 수 있으며, 경구 또는 비경구 투여될 수 있다. On the other hand, as an example of the formulation, the active ingredient may be mixed or diluted with the carrier, or may be contained in a capsule, sachet, paper or other kind of carrier. The carrier can then be a solid, semisolid, or liquid substance that acts as a vehicle, excipient or medium for the active ingredient to serve as a diluent. Thus, the resulting formulation may be in the form of tablets, pills, dispersants, granules, elixirs, suspensions, emulsifiers, solutions, syrups, aerosols, soft and hard gelatin capsules, sterile injectable solutions, sterile packaged powders and ointments, etc. It may be administered orally or parenterally.
이와같은 방법으로 얻어진 파에오놀 제제는 투여후 활성 성분을 급속하게, 지속적으로 또는 필요에 따라서는 지연시켜 방출할 수 있으며, 보다 구체적으로는 항산화, 항염증, 항암, 진정작용, 동맥경화저하등 성인병의 예방ㆍ치료에 효과적인 건강기능성 식품 조성물 및 약학적 조성물로서 사용할 수 있다. Paeonol preparations obtained in this way can release the active ingredient rapidly, continuously or delayed as necessary after administration, more specifically in adult diseases such as antioxidant, anti-inflammatory, anti-cancer, sedative, and atherosclerosis. It can be used as a health functional food composition and a pharmaceutical composition, which are effective for the prevention and treatment of pneumonia.
또한, 활성 화합물로서 파에오놀의 1일 투여량은 통상적으로 체중 1kg당 약0.1-20 mg의 범위내이면 충분하며, 건강보조용 기능성 식품 혹은 약학적 조성물로 사용할 경우 물, 또는 에탄올 추출물로서 환산값으로 체중 1kg당 100mg 내지 10 g의 범위내이면 충분하다. In addition, the daily dosage of paeonol as the active compound is usually within the range of about 0.1-20 mg per kg of body weight, and when used as a functional food or pharmaceutical composition for health supplements, it is converted into water or ethanol extract. In the range of 100 mg to 10 g per kg of body weight is sufficient.
실시예 Example
이하, 도면을 참조하여 본 발명의 실시형태를 상세하게 예시한다. 다만, 하기 실시예는 본 발명을 예시하는 것으로, 본 발명을 이에 한정하는 것은 아니다.EMBODIMENT OF THE INVENTION Hereinafter, embodiment of this invention is described in detail with reference to drawings. However, the following examples are illustrative of the present invention, and the present invention is not limited thereto.
실시예 1- 목단피의 가열처리가 파에오놀의 함량에 미치는 영향Example 1 Effect of Heat Treatment of Bark Bark on Paeonol Content
본 실시예는 목단피를 가열처리함으로써 파에오놀의 함량에 미치는 영향에 대하여 도 1을 참조한다. This embodiment refers to Figure 1 for the effect on the content of paeonol by heat treatment of the bark skin.
우선 도 1의 흐름도에서 나타낸 바와 같이, 목단피를 수집하여 이물질을 제거한 다음 잘게 자르거나 부수고, 그 500g을 전기볶음 기계를 이용하여 190℃에서 30분간 가열한 다음 80℃에서 95% 에탄올로 환류 추출한 다음 여과하고, 그 여액을 감압농축 하여 추출물 84.56g을 얻었다.First, as shown in the flowchart of FIG. 1, the bark skin is collected to remove foreign matter, and then finely chopped or crushed, the 500g is heated at 190 ° C for 30 minutes using an electric roasting machine, and then refluxed with 95% ethanol at 80 ° C. The filtrate was concentrated under reduced pressure to give 84.56 g of extract.
이와 같이 하여 얻어진 추출물을 증류수 1ℓ에 분산시킨 다음 동량의 디클로 로메탄으로 3회 분배추출하고 디클로로메탄에 가용성인 부분만을 혼합하여 농축시킴으로써 디클로로메탄 가용성 분획으로서 10.46g을 얻었다.The extract thus obtained was dispersed in 1 L of distilled water and then partitioned and extracted three times with the same amount of dichloromethane, followed by concentrating by mixing only the soluble portion in dichloromethane to obtain 10.46 g as the dichloromethane soluble fraction.
그런 다음, 상기 디클로로메탄 가용성 분획에 대하여 실리카젤 컬럼 크로마토그래피 (머크사제, No.7734, 컬럼크기 4, 54.5cm, 용출액: 핵산-에틸아세테이트-아세트산= 100-1-1%부터 시작하여 1-1-1%로 기울기를 주어 용출)를 수행하여 13개의 분획을 얻었으며, 이중 3번째 분획에서 HPLC상 순도 95%인 파에오놀 6.23g을 얻어내었다. Then, silica gel column chromatography (Merck, No.7734, column size 4, 54.5 cm, eluent: nucleic acid-ethyl acetate-acetic acid = 100-1-1%) was used for the dichloromethane soluble fraction. 13 fractions were obtained by eluting with a slope of 1-1%, and 6.23 g of paeonol having 95% purity on HPLC was obtained from the third fraction.
본 실험에서 분리한 파에오놀(paeonol) (HPLC UV 280 nm상 순도 95% 이상)을 표준물질로 하여 HPLC에서의 피크 지역(peak area) 과 농도간의 상관관계를 이용하여 검량선 [Y(peak area) = 0.0469 × X (concentration in μg) + 0.0014625, r2 = 0.9948]을 작성하였으며 미지농도의 피크 지역(peak area)를 상관관계식에 대입하여 파에오놀(paeonol)의 함량을 정량하였다. 로스팅(Roasting) 처리 후 증가하는 파에오놀의 함량을 정량하기 위하여 로스팅(roasting) 처리 후 목단피 에탄올 추출물 10 mg을 1 ml의 에탄올에 녹인 후, 4.5 μm 막 필터(membrane filter)로 여과 후 이 중 20 ㎕를 HPLC로 분석하였다. HPLC 조건은 1%의 아세트산(acetic acid)를 포함한 아세토니트릴(acetonitrile)을 0%에서 100%가 되도록 60분간 농도구배를 주어 분석하였다. 사용된 컬럼(column)은 ZORBAX Eclipse XDB-C18 (4.6×150 mm, 5 μm, Agilent, USA)이며, 유속은 0.8 ml/min, 검출은 280 nm에서 하였다. Using paeonol (95% purity over HPLC UV 280 nm) isolated from this experiment as a reference material, the calibration curve [Y (peak area) was calculated using the correlation between peak area and concentration in HPLC. = 0.0469 × X (concentration in μg) + 0.0014625, r 2 = 0.9948] and the paeonol content was quantified by substituting the peak area of unknown concentration into the correlation. After roasting, 10 mg of ethanol extract of bark ethanol was dissolved in 1 ml of ethanol, and then filtered through a 4.5 μm membrane filter after roasting. Μl was analyzed by HPLC. HPLC conditions were analyzed by giving a concentration gradient of 60% so that acetonitrile containing 1% acetic acid (acetonitrile) from 0% to 100%. The column used was ZORBAX Eclipse XDB-C18 (4.6 × 150 mm, 5 μm, Agilent, USA), flow rate 0.8 ml / min, detection at 280 nm.
부가하여 상기 공정을 5회 반복실시하고 이를 에탄올 추출물 1g 기준으로 환산한 환산치를 표 1에 함께 나타내었다. In addition, the process was repeated five times, and the converted value thereof based on 1 g of ethanol extract is shown in Table 1 together.
상기표에서 보듯이, 파에오놀 함량을 에탄올 추출물 1g으로 환산한 환산치는 454.3±5.7mg이었다. As shown in the table above, the conversion value of paonol content to 1 g of ethanol extract is 454.3 ± 5.7 mg.
비교예- 가열처리하지 않은 목단피로부터 얻어낸 파에오놀의 함량Comparative Example-Content of Paeonol from Unheated Bark Bark
가열처리 공정을 제외하고는 상기 실시예 1과 동일한 공정을 반복수행하여 얻어진 파에오놀 함량은 2.00g이었다. Except for the heat treatment step, the paeonol content obtained by repeating the same process as in Example 1 was 2.00 g.
상기 공정을 4회 반복하고 얻어진 파에오놀 함량 및 이를 목단피의 에탄올 추출물 1g을 기준으로 환산한 환산치를 표 2에 함께 나타내었다. The above process was repeated four times, and the paeonol content obtained and the converted value thereof based on 1 g of ethanol extract of bark skin are shown in Table 2 together.
상기표에서 보듯이, 파에오놀 함량을 에탄올 추출물 1g으로 환산한 환산치는 142.4±3.3mg이었다. 따라서, 상기표 1과 2를 대비한 결과, 본 발명의 방법을 수행함으로써 종래에 비하여 파에오놀 함량을 최대 3배까지 상승시킬 수 있음을 확인할 수 있다. As shown in the table above, the conversion value of paonol content to 1 g of ethanol extract is 142.4 ± 3.3 mg. Therefore, as a result of comparing the Tables 1 and 2, it can be seen that by performing the method of the present invention can increase the paeonol content up to three times as compared to the prior art.
실시예 2- 파에오놀의 확인Example 2- Identification of Paeonol
본 실시예는 가열처리후 목단피내 함량이 증강된 물질이 순수 파에오놀인지를 확인하고자 실험한 것으로, 도 2 내지 4를 참조한다. The present embodiment was tested to determine whether the substance enhanced in the neck dermal content after heat treatment is pure paeonol, see FIGS. 2 to 4.
HPLC 크로마토그램HPLC chromatogram
우선, 실시예 1에서 얻어진 목단피의 에탄올 추출물과 비교예에서 얻어진 목단피의 에탄올 추출물(대조군)에 대한 목단피내 파에오놀의 함량변화를 HPLC 크로마토그램을 이용하여 측정하고 그 결과를 도 2에 도시하였다. First, the change in the content of the ethanol extract of the bark skin obtained from Example 1 and the ethanol extract of the bark skin obtained from the comparative example (control) was measured using HPLC chromatogram, and the results are shown in FIG. 2.
도 2에서 확인할 수 있듯이, 상단의 대조군에서는 매우 작은 파에오놀 피크를 보이는데 반해, 하단의 실시예에서는 그 피크가 매우 증가한 것을 확인할 수 있었다. As can be seen in Figure 2, the upper control shows a very small paeonol peak, while in the lower example it was confirmed that the peak was increased very much.
자기공명 스펙트럼Magnetic resonance spectrum
또한, 상기 목단피 추출물중 함량이 매우 증가된 물질에 대한 수소 핵자기 공명 스펙트럼과 탄소 핵자기 공명 스펙트럼을 측정하고 그 결과를 각각 도 3 및 4 에 나타내었다. In addition, the hydrogen nuclear magnetic resonance spectra and the carbon nuclear magnetic resonance spectra for the substances having a very high content of the bark skin extract were measured and the results are shown in FIGS. 3 and 4, respectively.
도 3 및 4로부터 보듯이, 각 핵자기공명스펙트럼의 결과와 파에오놀이 나타내는 특성이 정확히 일치하였으므로, 이 화합물을 파에오놀로 동정하였다.As shown in Figs. 3 and 4, the results of the respective nuclear magnetic resonance spectra and the characteristics exhibited by paeool were exactly the same, and this compound was identified as paeonol.
실시예 3- 목단피의 최적 가열온도 확인Example 3 Confirmation of Optimal Heating Temperature of Bark Bark
본 실시예는 목단피를 가열처리시 최적 온도를 확인하기 위한 것으로 도 5를 참조한다. This embodiment refers to Figure 5 as to determine the optimum temperature during heat treatment of the neck skin.
실시예 1에서 얻어진 추출물에 대한 가열온도별 파에오놀 함량변화를 측정하고 그 결과를 도 5에 나타내었다. 도 5에서 보듯이, 50~210℃ 범위내에서 파에오놀의 함량이 개선됨을 확인할 수 있었으며, 140~200℃에서 파에오놀의 생성이 현저히 증가되었으며, 180~200℃부근에서 파에오놀의 생성이 극대화됨을 확인할 수 있었다.The change in paeonol content according to heating temperature for the extract obtained in Example 1 was measured and the results are shown in FIG. 5. As shown in Figure 5, it was confirmed that the content of paeonol in the range of 50 ~ 210 ℃ was improved, the production of paeonol was significantly increased at 140 ~ 200 ℃, maximizing the production of paeonol around 180 ~ 200 ℃ It could be confirmed.
실시예 4- 목단피의 최적 가열시간 확인Example 4- Confirmation of Optimal Heating Time of Bark Skin
본 실시예는 목단피를 가열처리시 최적 시간을 확인하기 위한 것이다. This embodiment is for confirming the optimum time during heat treatment of the neck skin.
실시예 3에서 얻어진 최적 가열온도를 감안하여 실시예 1에서 얻어진 목단피 추출물에 대한 가열시간별 파에오놀 함량변화를 측정하고 그 결과를 하기표 3에 나타내었다. In consideration of the optimum heating temperature obtained in Example 3, the change in paeonol content by heating time for the extract of wood bark obtained in Example 1 was measured and the results are shown in Table 3 below.
상기표에서 보듯이, 50~210℃ 온도에서 5~60분간 가열시키면 파에오놀의 함량이 개선됨을 확인할 수 있었으며, 140~200℃온도에서 20~60분간 가열시키면 파에오놀의 생성이 현저히 증가되었으며, 180~200℃부근에서 20~60분간 가열시키면 파에오놀의 생성이 극대화됨을 확인할 수 있었다.As shown in the above table, it was confirmed that the content of paeonol was improved by heating for 5 to 60 minutes at a temperature of 50 to 210 ° C, and the production of paonol was significantly increased by heating for 20 to 60 minutes at a temperature of 140 to 200 ° C. When heated for 20 to 60 minutes in the vicinity of 180 ~ 200 ℃ it was confirmed that the production of paeonol is maximized.
실시예 5- 항산화 활성도 측정Example 5- Antioxidant Activity Measurement
본 실시예는 DPPH 항산화 활성도를 측정하기 위한 것으로 도 6을 참조한다. This example refers to FIG. 6 for measuring DPPH antioxidant activity.
DPPH(1,1-디페닐-2-피크릴히드라질) 라디칼 소거활성은 브로이즈(Blois)의 방법에 준하여 수행하였다. 즉, 실시예 1에서 얻어진 각 25 및 100 ppm 농도를 갖는 시료들을 포함하는 200㎕의 에탄올 용액에 4X10-4 M DPPH 용액 800㎕를 가하여 10초간 혼합한 후 10분간 방치하고 525nm에서 흡광도를 측정한 다음 그 소거활성을 하기식에 의거하여 소거활성을 나타내었다. DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity was carried out according to the method of Brois. That is, 800 μl of 4 × 10 −4 M DPPH solution was added to 200 μl of ethanol solution containing samples having 25 and 100 ppm concentrations obtained in Example 1, mixed for 10 seconds, left for 10 minutes, and absorbance was measured at 525 nm. Next, the scavenging activity was shown based on the following formula.
(여기서, S는 시료를 가하였을 때 흡광도치이며, C는 시료를 포함하지 않는 200㎕의 에탄올 용액의 흡광도치이다)Where S is the absorbance value when the sample is added and C is the absorbance value of the 200 μl ethanol solution containing no sample.
상기 실험을 2회 반복한 다음 평균값을 계산하여 도 6에 나타내었으며, 이때 양성대조군으로서는 BHA(부틸화된 히드록시안니솔)를 사용하였다. 도 6에 도시한 그래프에서 확인할 수 있듯이, 가열처리에 의하여 약 10%정도 항산화 활성 증가를 나타냄을 확인할 수 있었다. The experiment was repeated twice and the average value was calculated and shown in FIG. 6, where BHA (butylated hydroxyanisole) was used as a positive control. As can be seen from the graph shown in Figure 6, it was confirmed that the antioxidant activity increased by about 10% by heat treatment.
한편 가열처리후 항산화활성의 변화 뿐 아니라 ACE (안지오텐신 전환 효소) 및 TNF-α (종양 네크로시스 팩터-α) 등에 대한 활성 변화를 측정하여 보았으나 뚜렸한 활성의 변화는 관찰되지 않았다.On the other hand, not only the change in antioxidant activity after heat treatment but also the activity changes on ACE (angiotensin converting enzyme) and TNF-α (tumor necrosis factor-α) were measured, but no significant change was observed.
본 발명은 상술한 실시예에 한정되는 것은 아니며, 본 발명의 사상을 벗어나지 않는 범위내에서 다양하게 수정 및 변형될 수 있다는 것은 이 기술의 분야에서 통상의 지식을 가진 자에게 자명하다. It is apparent to those skilled in the art that the present invention is not limited to the above-described embodiments, and that various modifications and changes can be made without departing from the spirit of the present invention.
즉, 본 발명에서는 목단피를 예로 들어 파에오놀의 함량 증강을 예시하고 있으나, 파에오놀을 함유하는 유사 식물류에 대한 동일한 가열처리를 통해서도 동일 내지는 유사한 효과를 얻을 수 있다. 따라서 그러한 변형예 또는 수정예들은 본 발명의 특허청구범위에 속하는 것이다.That is, in the present invention, for example, the content of paeonol is increased by taking the bark of the bark, but the same or similar effects may be obtained through the same heat treatment on the similar plants containing paeonol. Therefore, such modifications or variations are intended to fall within the claims of the present invention.
본 발명에 의하면, 항산화, 항염증, 항암, 진정작용, 동맥경화 저해등 활성화합물인 파에오놀 함량을 증강시켜 추출해낼 수 있다. According to the present invention, it is possible to extract by increasing the content of paeonol active compounds such as antioxidant, anti-inflammatory, anti-cancer, sedation, inhibiting atherosclerosis.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050004083A KR20060084083A (en) | 2005-01-17 | 2005-01-17 | Method for Purifying Painol Intradermal |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050004083A KR20060084083A (en) | 2005-01-17 | 2005-01-17 | Method for Purifying Painol Intradermal |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20060084083A true KR20060084083A (en) | 2006-07-24 |
Family
ID=37174233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050004083A Ceased KR20060084083A (en) | 2005-01-17 | 2005-01-17 | Method for Purifying Painol Intradermal |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20060084083A (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101975833A (en) * | 2010-05-25 | 2011-02-16 | 江西中烟工业有限责任公司 | Method for measuring main active ingredient paeonol of traditional Chinese medicinal additive in cigarettes |
CN102908648A (en) * | 2012-10-24 | 2013-02-06 | 合肥工业大学 | Gel type paeonol air freshener |
CN103196712A (en) * | 2013-02-23 | 2013-07-10 | 安徽师范大学 | Preparation method for sample used for detection of paeonol in plant and detection method for paeonol |
CN103342670A (en) * | 2013-07-18 | 2013-10-09 | 山东方明药业集团股份有限公司 | Purifying method of sodium paeonolsilate |
US9066974B1 (en) | 2010-11-13 | 2015-06-30 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
US9095606B1 (en) | 2010-11-13 | 2015-08-04 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
CN105372378A (en) * | 2014-08-28 | 2016-03-02 | 神威药业集团有限公司 | Quality inspection method of cortex moutan dispersing granules |
CN105801392A (en) * | 2016-04-14 | 2016-07-27 | 重庆大学 | Extracting method of 2'-hydroxy-4'-methoxyacetopheone |
CN107118089A (en) * | 2017-05-16 | 2017-09-01 | 广州市娇兰化妆品有限公司 | A kind of method that paeonol is prepared from plant and the application in cosmetics are prepared |
CN107142152A (en) * | 2017-05-18 | 2017-09-08 | 西北农林科技大学 | A kind of peony seed oil complex natural antioxidant containing paeonol |
CN111018738A (en) * | 2019-12-20 | 2020-04-17 | 安徽医科大学 | Paeonol derivative, pharmaceutical preparation, preparation method and application |
KR20200073015A (en) * | 2018-12-13 | 2020-06-23 | (주)아모레퍼시픽 | Pretreatment technology for enhancing physiological activity of plant extracts of paeonia |
CN112961729A (en) * | 2021-03-24 | 2021-06-15 | 西北农林科技大学 | Method for optimizing extraction of peony hydrolat under negative pressure distillation condition |
CN113861003A (en) * | 2021-11-04 | 2021-12-31 | 山东东宇生态科技有限公司 | A kind of extraction method of paeonol in Cortex Moutan |
-
2005
- 2005-01-17 KR KR1020050004083A patent/KR20060084083A/en not_active Ceased
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101975833A (en) * | 2010-05-25 | 2011-02-16 | 江西中烟工业有限责任公司 | Method for measuring main active ingredient paeonol of traditional Chinese medicinal additive in cigarettes |
CN101975833B (en) * | 2010-05-25 | 2013-04-17 | 江西中烟工业有限责任公司 | Method for measuring main active ingredient paeonol of traditional Chinese medicinal additive in cigarettes |
US9066974B1 (en) | 2010-11-13 | 2015-06-30 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
US9095606B1 (en) | 2010-11-13 | 2015-08-04 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
CN102908648A (en) * | 2012-10-24 | 2013-02-06 | 合肥工业大学 | Gel type paeonol air freshener |
CN103196712A (en) * | 2013-02-23 | 2013-07-10 | 安徽师范大学 | Preparation method for sample used for detection of paeonol in plant and detection method for paeonol |
CN103196712B (en) * | 2013-02-23 | 2016-04-13 | 安徽师范大学 | Paeonol detection sample preparation methods and Paeonol detection method in plant |
CN103342670A (en) * | 2013-07-18 | 2013-10-09 | 山东方明药业集团股份有限公司 | Purifying method of sodium paeonolsilate |
CN105372378A (en) * | 2014-08-28 | 2016-03-02 | 神威药业集团有限公司 | Quality inspection method of cortex moutan dispersing granules |
CN105801392A (en) * | 2016-04-14 | 2016-07-27 | 重庆大学 | Extracting method of 2'-hydroxy-4'-methoxyacetopheone |
CN107118089A (en) * | 2017-05-16 | 2017-09-01 | 广州市娇兰化妆品有限公司 | A kind of method that paeonol is prepared from plant and the application in cosmetics are prepared |
CN107118089B (en) * | 2017-05-16 | 2021-03-23 | 广州市娇兰化妆品有限公司 | Method for preparing paeonol from plant and application of paeonol in preparation of cosmetics |
CN107142152A (en) * | 2017-05-18 | 2017-09-08 | 西北农林科技大学 | A kind of peony seed oil complex natural antioxidant containing paeonol |
CN107142152B (en) * | 2017-05-18 | 2021-10-12 | 西北农林科技大学 | Peony seed oil composite natural antioxidant containing paeonol |
KR20200073015A (en) * | 2018-12-13 | 2020-06-23 | (주)아모레퍼시픽 | Pretreatment technology for enhancing physiological activity of plant extracts of paeonia |
CN111018738A (en) * | 2019-12-20 | 2020-04-17 | 安徽医科大学 | Paeonol derivative, pharmaceutical preparation, preparation method and application |
CN111018738B (en) * | 2019-12-20 | 2023-03-21 | 安徽医科大学 | Paeonol derivative, pharmaceutical preparation, preparation method and application |
CN112961729A (en) * | 2021-03-24 | 2021-06-15 | 西北农林科技大学 | Method for optimizing extraction of peony hydrolat under negative pressure distillation condition |
CN112961729B (en) * | 2021-03-24 | 2023-10-13 | 西北农林科技大学 | Method for extracting peony hydrosol under optimized negative pressure distillation condition |
CN113861003A (en) * | 2021-11-04 | 2021-12-31 | 山东东宇生态科技有限公司 | A kind of extraction method of paeonol in Cortex Moutan |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20060084083A (en) | Method for Purifying Painol Intradermal | |
US7977516B2 (en) | Process of obtainment of trans-resveratrol and/or emodin and nutraceutical compositions containing them | |
KR20120006029A (en) | Novel compound salvianolic acid L, preparation method and use thereof | |
CN101380390B (en) | Preparation method of Pu-Er ripe tea standard extract PRC-001 and preparation method and use thereof | |
KR101382099B1 (en) | Anticonvulsive compositions comprising aster glehni extract, fractions thereof, or compounds isolated from thereform | |
JP2002267655A (en) | Plant of genus euonymus family salacia and/or method of judging quality in extract from the plant | |
WO2011065799A2 (en) | Preparation method of tea water, and tea water obtained thereby | |
Xia et al. | Antioxidant activity of Chinese mei (Prunus mume) and its active phytochemicals | |
CN109942649B (en) | Indole glycoside compound and extraction and separation method and application thereof | |
CN102657362B (en) | Method for improving mouthfeel of exocarpium citri grandis extract obviously and application of exocarpium citri grandis extract | |
KR0180688B1 (en) | Skin whitening composition using extracts from asparagus cochinchinensis merrill | |
KR101062174B1 (en) | Triterpenoid compounds activating AMPK obtained from persimmon leaves and compositions for the prevention and treatment of obesity or diabetes comprising the same as an active ingredient | |
CN111848565B (en) | Monoterpene bishydroxycoumarin compound, pharmaceutical composition, preparation method and application thereof | |
CN103130851A (en) | Method of preparing four kinds of pelargonidin derivatives from radish peel in a separating mode | |
JP4772190B2 (en) | Skin lightening agent | |
KR100313323B1 (en) | Method for Extraction Isolation and Identification of trans-Resveratrol from Paeonia lactiflora Seeds | |
KR101500836B1 (en) | Complex extract of Quercus variabilis fractions and composition for treating or preventing diabetes comprising the same | |
KR100750500B1 (en) | Novel Saga Chromamanol Derivative Compounds Having Antioxidant Activity, Separation Methods thereof, and Antioxidants Including the Same | |
CN106317000B (en) | Salvianolic acid compound, preparation method and application thereof | |
KR100757130B1 (en) | Skin whitening cosmetics containing verazine and epi-verazine with melanin inhibitory activity | |
KR100659771B1 (en) | Purification of Anticancer Compound Berutin and Beturin Acid from Korean Mistletoe Organic Extracts and Method of Preparing the Extract | |
JP4437019B2 (en) | Alcohol extract of Ranunculaceae and its uses | |
KR100490682B1 (en) | A process for isolating epi-oleanolic acid from Viscum album coloratum | |
EP1840131B1 (en) | Novel polyphenol glycoside derived from acerola | |
KR100765436B1 (en) | Method for increasing the content of aurantio-optucin in the deficiency and method for purifying aurantithio-optucin with increased content |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20050117 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060224 Patent event code: PE09021S01D |
|
E90F | Notification of reason for final refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20060718 Patent event code: PE09021S02D |
|
PG1501 | Laying open of application | ||
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20060929 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20060718 Comment text: Final Notice of Reason for Refusal Patent event code: PE06011S02I Patent event date: 20060224 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |